Suspension administration pharmacokinetic case report
10 evidence topics · 1 source
Objective
Location and study date
Location and initial presentation date
Study design
Publication design
Eligibility criteria
Not applicable.
Treatment
Reported daily dose
Study outcomes
Rationale for using plasma Tirabrutinib concentration as an exploratory outcome
Clinical bioequivalence validation
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Discharge after treatment initiation
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Comparable measured concentrations in a single case do not establish bioequivalence, a limitation explicitly acknowledged by the authors. No adverse events were observed during suspension administration; this observation does not estimate the frequency of uncommon harms.